Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   JOURNAL OF ISFAHAN MEDICAL SCHOOL (I.U.M.S)   DECEMBER 2010 , Volume 28 , Number 112; Page(s) 632 To 639.
 
Paper: 

EFFECT OF PIOGLITAZONE ON PROTEINURIA IN NON-DIABETIC RENAL PATIENTS: A SELF-CONTROL CLINICAL TRIAL

 
 
Author(s):  SHAHIDI SHAHRZAD, PAKZAD BAHRAM, MORTAZAVI MOJGAN*, SEIRAFIAN SHIVA, AKBARI MOJTABA, ATARPOUR ABDOLAMIR, SHAYGAN NEZHAD ALIREZA
 
* ISFAHAN KIDNEY DISEASES RESEARCH CENTER, DEPARTMENT OF NEPHROLOGY, SCHOOL OF MEDICINE, ISFAHAN UNIVERSITY OF MEDICAL SCIENCES, ISFAHAN, IRAN
 
Abstract: 
Background: Proteinuria has independent deleterious effects on the progression of chronic renal disease.
The aim of this study was to determine effect of pioglitazone on proteinuria in patients with non-diabetic renal disease.
Methods: This was a self-controlled clinical trial study conducted in Al-Zahara Hospital and few private clinics of nephrology in Isfahan. Forty four non- diabetic patients aged 18 and over, who had renal disease and stable proteinuria over 0.5 g in 24h and body mass index (BMI) lower than 30 kg/m2 , were enrolled in the study. Patients were treated by 15 mg of pioglitazone for 4 months. The primary end point was urine protein excretion, measured prior to the study, at the end of 2 and 4 months during treatment as well as 2 months after cessation of pioglitazone. Secondary end points included systolic blood pressure, creatinine, ALT, AST, FBS, BUN and GFR levels.
Findings: Mean urine protein excretion was 1088.6
±775.6 mg124h before treatment; therefore mean urine protein excretion at the end of 4th month was 433.9±406.2 mg/24 h (P<0.001, CI 95%: 0.49-0.82).
There was no significant trend for systolic blood pressure, creatinine, ALT, AST, FBS, BUN and GFR levels to increase or decrease during the follow-up period (P>0.01).
Conclusion: Consietering complication s of proteinuria followed by gradual kidney malfunction based on findings of present study, pioglitazone could significantly decrease proteinuria in patients with non-diabetic kidney diseases.
 
Keyword(s): PROTEINURIA, PIOGLITAZONE, NON-DIABETIC RENAL DISEASE, HYPOGLYCEMIC AGENT
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

SHAHIDI, S., & PAKZAD, B., & MORTAZAVI, M., & SEIRAFIAN, S., & AKBARI, M., & ATARPOUR, A., & SHAYGAN NEZHAD, A. (2010). EFFECT OF PIOGLITAZONE ON PROTEINURIA IN NON-DIABETIC RENAL PATIENTS: A SELF-CONTROL CLINICAL TRIAL. JOURNAL OF ISFAHAN MEDICAL SCHOOL (I.U.M.S), 28(112), 632-639. https://www.sid.ir/en/journal/ViewPaper.aspx?id=276982



Vancouver: Copy

SHAHIDI SHAHRZAD, PAKZAD BAHRAM, MORTAZAVI MOJGAN, SEIRAFIAN SHIVA, AKBARI MOJTABA, ATARPOUR ABDOLAMIR, SHAYGAN NEZHAD ALIREZA. EFFECT OF PIOGLITAZONE ON PROTEINURIA IN NON-DIABETIC RENAL PATIENTS: A SELF-CONTROL CLINICAL TRIAL. JOURNAL OF ISFAHAN MEDICAL SCHOOL (I.U.M.S). 2010 [cited 2021July31];28(112):632-639. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=276982



IEEE: Copy

SHAHIDI, S., PAKZAD, B., MORTAZAVI, M., SEIRAFIAN, S., AKBARI, M., ATARPOUR, A., SHAYGAN NEZHAD, A., 2010. EFFECT OF PIOGLITAZONE ON PROTEINURIA IN NON-DIABETIC RENAL PATIENTS: A SELF-CONTROL CLINICAL TRIAL. JOURNAL OF ISFAHAN MEDICAL SCHOOL (I.U.M.S), [online] 28(112), pp.632-639. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=276982.



 
 
Persian Abstract Yearly Visit 36
 
 
Latest on Blog
Enter SID Blog